GlassScriptPhysician profile
Faviola Marin
NPI 1598136350
$372.05
in general payments reported to CMS, 2019-2025
11 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $126 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $57.81 | 2025 | |
| Abbvie INC. | $49.12 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $45.36 | 2024 | Airsupra, Farxiga |
| Exact Sciences Corporation | $38.21 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $36.82 | 2024 | Ozempic, Wegovy |
| Sumitomo Pharma America, INC. | $29.62 | 2024 | Myfembree |
| Kowa Pharmaceuticals America, INC. | $29.54 | 2024-2025 | Zoryve |
| Aimmune Therapeutics, INC. | $25.15 | 2025 | Zenpep |
| Lilly USA, LLC | $21.50 | 2025 | Zepbound, Mounjaro |
| Madrigal Pharmaceuticals | $21.08 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $17.84 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faviola Marin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.